242 related articles for article (PubMed ID: 23397008)
1. Prognostic value of interim and posttherapy 18F-FDG PET/CT in patients with mature T-cell and natural killer cell lymphomas.
Li YJ; Li ZM; Xia XY; Huang HQ; Xia ZJ; Lin TY; Li S; Xia Y; Cai XY; Jiang WQ
J Nucl Med; 2013 Apr; 54(4):507-15. PubMed ID: 23397008
[TBL] [Abstract][Full Text] [Related]
2. Midtreatment ¹⁸F-FDG PET/CT Scan for Early Response Assessment of SMILE Therapy in Natural Killer/T-Cell Lymphoma: A Prospective Study from a Single Center.
Khong PL; Huang B; Lee EY; Chan WK; Kwong YL
J Nucl Med; 2014 Jun; 55(6):911-6. PubMed ID: 24819420
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the prognostic capacity of pretreatment, interim, and post-therapy (18)F-FDG PET/CT in extranodal natural killer/T-cell lymphoma, nasal type.
Jiang C; Zhang X; Jiang M; Zou L; Su M; Kosik RO; Tian R
Ann Nucl Med; 2015 Jun; 29(5):442-51. PubMed ID: 25801633
[TBL] [Abstract][Full Text] [Related]
4. 18F-fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature T/NK lymphomas: a study from the GOELAMS group.
Cahu X; Bodet-Milin C; Brissot E; Maisonneuve H; Houot R; Morineau N; Solal-Celigny P; Godmer P; Gastinne T; Moreau P; Moreau A; Lamy T; Kraber-Bodere F; Le Gouill S
Ann Oncol; 2011 Mar; 22(3):705-711. PubMed ID: 20739714
[TBL] [Abstract][Full Text] [Related]
5. The Deauville 5-Point Scale Improves the Prognostic Value of Interim FDG PET/CT in Extranodal Natural Killer/T-Cell Lymphoma.
Jiang C; Su M; Kosik RO; Zou L; Jiang M; Tian R
Clin Nucl Med; 2015 Oct; 40(10):767-73. PubMed ID: 26164182
[TBL] [Abstract][Full Text] [Related]
6. 18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma.
Casulo C; Schöder H; Feeney J; Lim R; Maragulia J; Zelenetz AD; Horwitz S
Leuk Lymphoma; 2013 Oct; 54(10):2163-7. PubMed ID: 23369041
[TBL] [Abstract][Full Text] [Related]
7. 18F-FDG PET/CT for Prognostic Stratification of Patients With Extranodal Natural Killer/T-Cell Lymphoma.
Qin C; Yang S; Sun X; Xia X; Li C; Lan X
Clin Nucl Med; 2019 Mar; 44(3):201-208. PubMed ID: 30624268
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma.
Yang DH; Min JJ; Song HC; Jeong YY; Chung WK; Bae SY; Ahn JS; Kim YK; Bom HS; Chung IJ; Kim HJ; Lee JJ
Eur J Cancer; 2011 Jun; 47(9):1312-8. PubMed ID: 21334197
[TBL] [Abstract][Full Text] [Related]
9. Prognostic values of interim and post-therapy 18F-FDG PET/CT scanning in adult patients with Burkitt's lymphoma.
Wei WX; Huang JJ; Li WY; Zhang X; Xia Y; Jiang WQ; Fan W; Li ZM
Chin J Cancer; 2015 Dec; 34(12):608-13. PubMed ID: 26630874
[TBL] [Abstract][Full Text] [Related]
10. Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies.
Khong PL; Pang CB; Liang R; Kwong YL; Au WY
Ann Hematol; 2008 Aug; 87(8):613-21. PubMed ID: 18509641
[TBL] [Abstract][Full Text] [Related]
11. The value of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma.
Karantanis D; Subramaniam RM; Peller PJ; Lowe VJ; Durski JM; Collins DA; Georgiou E; Ansell SM; Wiseman GA
Clin Lymphoma Myeloma; 2008 Apr; 8(2):94-9. PubMed ID: 18501102
[TBL] [Abstract][Full Text] [Related]
12. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
Berthet L; Cochet A; Kanoun S; Berriolo-Riedinger A; Humbert O; Toubeau M; Dygai-Cochet I; Legouge C; Casasnovas O; Brunotte F
J Nucl Med; 2013 Aug; 54(8):1244-50. PubMed ID: 23674577
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of negative interim 2-[¹⁸F]-fluoro-2-deoxy-d-glucose PET/CT in diffuse large B-cell lymphoma.
Kwon SH; Kang DR; Kim J; Yoon JK; Lee SJ; Jeong SH; Lee HW; An YS
Clin Radiol; 2016 Mar; 71(3):280-6. PubMed ID: 26732889
[TBL] [Abstract][Full Text] [Related]
14. Early determination of prognosis by interim 3'-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma.
Lee H; Kim SK; Kim YI; Kim TS; Kang SH; Park WS; Yun T; Eom HS
J Nucl Med; 2014 Feb; 55(2):216-22. PubMed ID: 24365650
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic value of PET-CT in patients with diffuse large B-cell lymphoma].
Ding C; Li T; Sun J; Yang W; Ding Q; Xu X
Zhonghua Zhong Liu Za Zhi; 2014 Dec; 36(12):923-7. PubMed ID: 25623768
[TBL] [Abstract][Full Text] [Related]
16. Predictive approaches for post-therapy PET/CT in patients with extranodal natural killer/T-cell lymphoma: a retrospective study.
Jiang C; Liu J; Li L; Kosik RO; Su M; Zou L; Tian R
Nucl Med Commun; 2017 Nov; 38(11):937-947. PubMed ID: 28858180
[TBL] [Abstract][Full Text] [Related]
17. Utility of interim and end-of-treatment PET/CT in peripheral T-cell lymphomas: A review of 124 patients.
El-Galaly TC; Pedersen MB; Hutchings M; Mylam KJ; Madsen J; Gang AO; Bøgsted M; de Nully Brown P; Loft A; Nielsen AL; Hendel HW; Iyer V; Gormsen LC
Am J Hematol; 2015 Nov; 90(11):975-80. PubMed ID: 26201505
[TBL] [Abstract][Full Text] [Related]
18. The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma.
Avigdor A; Sirotkin T; Kedmi M; Ribakovsy E; Berkowicz M; Davidovitz Y; Kneller A; Merkel D; Volchek Y; Davidson T; Goshen E; Apter S; Shimoni A; Ben-Bassat I; Nagler A
Ann Hematol; 2014 Aug; 93(8):1297-304. PubMed ID: 24595734
[TBL] [Abstract][Full Text] [Related]
19. The combined evaluation of interim contrast-enhanced computerized tomography (CT) and FDG-PET/CT predicts the clinical outcomes and may impact on the therapeutic plans in patients with aggressive non-Hodgkin's lymphoma.
Yang DH; Min JJ; Jeong YY; Ahn JS; Kim YK; Cho SH; Chung IJ; Bom HS; Kim HJ; Lee JJ
Ann Hematol; 2009 May; 88(5):425-32. PubMed ID: 19002686
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of interim 18F-FDG PET/CT in T-cell lymphomas.
Qian L; Yan M; Zhang W; Zhou D; Zhang Y; Huo L; Luo Y; Zhang Y; Hu S
Leuk Lymphoma; 2020 Apr; 61(4):927-933. PubMed ID: 31795794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]